Boston, MA (PRWEB) May 20, 2021 Leading off the morning’s presentations in MarketsandMarkets’ Virtual 5th Annual Bioprocessing of Biotherapeutics – UK, EU
Asymmetrex Discusses a Near Horizon for Stem Cell Dosage in Stem Cell Therapy and Gene Therapy Clinical Trial Supply Chains
Share Article
Today, May 11, in the Clinical Trial Supply USA 2021 – Virtual Conference, the President and CEO of stem cell biotechnology company Asymmetrex, James L. Sherley, M.D., Ph.D., discussed new developments on the horizon for the supply chains for stem cell therapy and gene therapy clinical trials. In particular, he suggested that it is inevitable that regulatory agencies like the FDA and clinical trial sponsors will eventually require stem cell dosage data for all supply chain activities, as well as for stem cell treatments.
Asymmetrex Will Discuss the Impact of Its Technology for Dosing Therapeutic Stem Cells
Share Article
During the coming months of May and June, stem cell biotechnology company Asymmetrex is invited to give presentations in several different virtual conferences that span the fields of clinical trial supply, cell biotherapeutics, stem cell science, and stem cell medicine. The company’s relevance to these diverse disciplines reflects the broad scope of the impact of its emerging technologies for determining the dosage of therapeutic stem cells.
Asymmetrex President & CEO
James L. Sherley, M.D., Ph.D.
It’s basic medicine. Finally knowing the stem cell dosage of stem cell treatments must necessarily be better for patients.